Double-Digit Growth Ahead for Aortic Valve Replacement Market

The future looks bright for the worldwide aortic valve replacement market.

Straits Research forecasts the sector to expand 14% annually through 2030 to reach $33.51 billion. Growth drivers include the rising number of valvular diseases like aortic stenosis and aortic regurgitation, as well as technological advances in the heart valve market. Aortic stenosis is the most common disease of a valve that affects older people. Aortic stenosis is the most common disease of a valve that affects older people and the world’s population is aging. The number of older people is expected to grow from 962 million in 2017 to 2.1 billion in 2050. The market is also expected to grow in the next few years because of the rise of minimally invasive surgeries like TAVR and the development of valves that do not need stitches. Several things are being done to let people know about aortic valve replacement, which is expected to have a positive effect on the market in the coming years.
 
Aortic regurgitation is another valve disease that can only be fixed with surgery (aortic valve replacement, or AVR). This problem happens more often as people age. Aortic regurgitation is usually caused by rheumatic heart disease, a type of heart inflammation that occurs for a long time. WHO (World Health Organization) estimates that about 2% of people with cardiovascular diseases (CVDs) have rheumatic heart diseases. Thus, the growing number of rheumatic heart diseases is likely to have a positive effect on the market in the coming years.
 
With the new techniques and treatment options available to cure or operate on a patient, more people are learning about them and getting referred to better care. Based on the numbers released by Medicare and Medicaid, the number of people over 65 with aortic stenosis is growing quickly. In 1989, there were only 2,500 people with this condition, but in 2011, there were more than 32,000. 
 
Along with this, good insurance and reimbursement policies are expected to be one of the most important factors driving the market in the coming years. For instance, the Centers for Medicare and Medicaid Services (CMS) said the Medicare National Coverage Determination policy would cover TAVR. In determining coverage for different procedures, different insurance companies have different rates. A heart valve replacement is a serious illness—coverage depends on the amount insured. 
 
Transcatheter aortic valves are frequently because more people want less invasive surgeries. Transcatheter valves are receiving more research and development funding and attention, and more patients worldwide are learning about TAVR. Key players in this market have conducted a number of clinical studies to test the safety, effectiveness, and range of interventions. Even though sutureless valves are not used very often, they offer a big chance for growth because they have so many benefits. Sutureless valves show good hemodynamic and post-surgery results and have a lower death rate.
 
Only the Enable 3F, the Perceval, and the Edwards Intuity Valve System have been put on the market without sutures. But there are a number of sutureless valves in development that could help the field of sutureless valves grow in the future. The rest of the valves are made of tissue valves and valves that are made of metal. There are already numerous metal valves on the market, but their growth is limited because new technologies like TAVR are coming out. With mechanical and tissue heart valves, developing economies have more room to grow than economies that are already doing well, which opens up huge opportunities.
 
Europe is leading the global aortic valve replacement market with a $3.53 billion value in 2021 and is expected to grow 11% annually to $9.11 billion by 2030. The high number of people with aortic stenosis, the development of effective treatments like TAVR, and more efforts to raise awareness about valve replacement surgeries are some of the main reasons why this market is growing. 
 
After Europe, North America is the second most important region for the aortic valve replacement market in terms of revenue. North America is known for having the most advanced healthcare facilities, and it is expected to grow at a rate of 10% over the next few years.
  
The Asia-Pacific region is third on the list, with a 14% compound annual growth rate through 2030—the highest expansion rate of all the regions. With this rate of growth, the Asia-Pacific region will soon lead the global aortic valve replacement market.
 
Minimal invasive surgery is the major dominant segment in the by-surgery type segmentation that accounted for a $5.83 billion market value last year in 2021 and is expected to grow 16% annually to $21.86 billion by 2030. 

The hospital segment in the by end-use category contributes the major share of the market with $3.95 billion in 2021 and swelling 13% annually to reach $11.41 billion by 2030.